Frédéric Joliot Institute for Life Sciences - On the same theme

Biotherapies: the risk of immunogenicity associated with nanobodies

Tue, 31 Mar 2026 10:00:00 GMT

Nanobodies, promising biotherapeutic agents, may trigger undesirable immune reactions. A team from SIMoS demonstrates, using a sensitive assay on human T lymphocytes, that this risk exists for certain nanobodies and can be reduced through sequence humanization. These findings highlight the importance of assessing immunogenicity alongside therapeutic efficacy.

Toward CAR-macrophage-based cellular immunotherapy for treating certain solid tumors?

Mon, 09 Mar 2026 11:00:00 GMT

Researchers from our DMTS department have published a study providing the first proof of concept for a CAR-macrophage therapy targeting the endothelin B receptor, which is overexpressed in melanoma cells.

Multiple Sclerosis: Assessing AI Tools for Prognostic Support

Mon, 02 Feb 2026 11:00:00 GMT

Researchers from the BioMaps laboratory (SHFJ) demonstrate the value of artificial intelligence software in interpreting MRI data for monitoring individuals with multiple sclerosis. However, validation by clinical radiologists remains essential to ensure the accuracy of the interpretation.

Opening the BBB to Deliver Drugs to the Brain: Removing Noise Signals to Optimize Focused Ultrasound Pressure Control Protocol

Wed, 14 Jan 2026 11:00:00 GMT

Teams from BioMaps (SHFJ) and BAOBAB (NeuroSpin), along with CEA-Jacob, are optimizing their strategy for opening the blood-brain barrier (BBB) using focused ultrasound (FUS) to deliver drugs to the brain. Their innovation: an algorithm that identifies and 'eclipses' extracranial cavitation induced by thick temporal muscles—particularly in large male primates—which otherwise masks the signal of interest.

PET Imaging Reveals the Effects of Ketamine on Synaptic Plasticity in a Model of Depression

Mon, 22 Dec 2025 11:00:00 GMT

Researchers from BioMaps (SHFJ) and MOODS have validated an innovative molecular neuroimaging approach that allows non-invasive monitoring of ketamine’s effects on synaptic density in a preclinical model of depression.

Reconstructing PET images more reliably with a convergent “Plug-and-Play” regularization approach

Tue, 16 Dec 2025 11:00:00 GMT

A team of researchers from BioMaps (SHFJ) is proposing a new reconstruction method for PET imaging that combines optimization algorithms with deep neural networks. Their “plug-and-play” regularization approach ensures improved image quality thanks to PET-specific reconstruction learning, while guaranteeing stability and robustness—two critical aspects in the use of AI-based medical techniques.

Using Light to Switch Off the MRI Signal of Micellar Probes for Diagnostic Purposes

Fri, 05 Dec 2025 11:00:00 GMT

Researchers at the SCBM and BAOBAB have developed a new version of their nanometric micellar vector designed for fluorine-19 magnetic resonance tumor imaging. This version is intended to enhance MRI contrast by switching off the signal on demand in certain areas, while preserving it in pathological regions to be imaged.

Proof of concept for the passage of trastuzumab formulated in nanoparticles through an in vitro-reconstituted nasal epithelium.

Wed, 12 Nov 2025 11:00:00 GMT

Researchers from SPI (DMTS) developed a formulation of PLGA nanoparticles loaded with the anticancer trastuzumab (NP-TZB) and measured their ability to cross a cellular model of the nasal epithelial barrier. This first validated step supports a potential nose-to-brain (N2B) delivery route.

PET imaging of OATP transporter-mediated drug elimination: impacts of sex and age

Wed, 15 Oct 2025 10:00:00 GMT

Researchers from BioMaps (SHFJ) investigated the hepatic activity of organic anion-transporting polypeptides (OATPs), key players in the elimination of certain drugs, using a PET imaging approach with 11C-glyburide, which revealed differences in tracer pharmacokinetics between men and women.

Développement de radioligands pour l’imagerie TEP de la neuroinflammation

Fri, 03 Oct 2025 10:00:00 GMT

Des chercheurs du SHFJ, en collaboration avec le CEA-Jacob, le CRN à Lyon et le PharmaCenter à Bonn ont imaginé, synthétisé et caractérisé deux radiotraceurs TEP ciblant P2Y12, une protéine impliquée dans l’activation de la microglie durant la neuroinflammation.

Ultrasound to counteract the cerebral effects of exposure to a neurotoxic agent

Thu, 28 Aug 2025 10:00:00 GMT

Researchers from BioMaps (SHFJ), NeuroSpin, and the french IRBA developed an innovative approach using focused ultrasound to improve brain delivery of an antidote, oxime, following exposure to an organophosphorus neurotoxic agent in a murine model.

Better understanding opioid tolerance through brain imaging

Wed, 06 Aug 2025 10:00:00 GMT

A study combining PET imaging and pharmacology, conducted by researchers at BioMaps (SHFJ), suggests that decreased availability of opioid receptors and altered neuronal energy metabolism constitute molecular signatures of opioid tolerance. These observations, made in an animal model, could help improve understanding and treatment of opioid dependence.

Correlation between neuroinflammation and epileptogenic zone in drug-resistant focal epilepsy

Tue, 15 Jul 2025 10:00:00 GMT

A study by SHFJ researchers has established a strong correlation between biomarkers of neuroinflammation, revealed by original PET imaging, and intracranial electroencephalographic recordings of epileptogenic activity. This offers hope for drug-resistant patients who are candidates for surgery.

Cancer : transformer la mertansine en prodrogue pour une chimiothérapie ciblée et moins toxique grâce à une approche théranostique.

Tue, 01 Jul 2025 10:00:00 GMT

Une équipe du laboratoire BioMaps, en collaboration avec l’Institut Galien Paris-Saclay a mis au point une stratégie innovante associant une prodrogue polymère et l'imagerie par tomographie par émission de positons (TEP) pour améliorer l'efficacité de la mertansine, un agent antitumoral puissant mais toxique.

A promising drug candidate for the treatment of neonatal hypoxic-ischemic encephalopathy

Thu, 26 Jun 2025 10:00:00 GMT

Researchers from the SPI (DMTS) and the Women & Infants Hospital in Providence have laid the molecular basis for the neuroprotection of a purine derivative in a preclinical model of neonatal hypoxic-ischemic encephalopathy (HIE). The promising results support the development of this drug candidate to treat HIE in neonates.

Theranostic antibodies targeting endothelin receptors in preclinical models of glioblastoma and melanoma

Thu, 22 May 2025 10:00:00 GMT

Researchers from SPI (DMTS) propose immunodiagnostic and immunotherapeutic approaches based on the use of innovative antibodies targeting two subtypes of endothelin receptors (ETA and ETB), recognised as relevant therapeutic targets in oncology.

Deutération : le déblocage d'un verrou méthodologique au potentiel industriel

Thu, 13 Feb 2025 11:00:00 GMT

Une étude menée par le SCBM présente une approche innovante permettant de relever les défis actuels des méthodes d'échange isotopique hydrogène - deutérium en offrant un processus efficace, reproductible et évolutif. Ave à la clef, de possibles développements industriels dans les domaines des médicaments et des technologies OLED.

Un test bandelette pour détecter les infections à Candida auris

Mon, 20 Jan 2025 11:00:00 GMT

Des chercheurs du LERI (SPI/DMTS), en collaboration avec NG Biotech, ont développé un test-bandelette de détection de Candida auris, un champignon à l’origine d’infections nosocomiales de plus en plus fréquentes. Leurs premiers résultats sur des souches isolées indiquent d’excellentes performances du dispositif.

Immunological profiling of cancer : when click-chemistry meets mass spectrometry

Mon, 13 Jan 2025 11:00:00 GMT

Researchers at DMTS and SHFJ have carried out a multiplexed analysis of tumor cells and tissues, based on the use of cleavable therapeutic antibodies carrying mass tags, for the identification and quantification of cancer biomarkers. A proof-of-concept demonstrating the high potential of this tumor immunoprofiling approach

SplineBeam : un algorithme réaliste et rapide pour prédire les champs de pression des ultrasons.

Thu, 24 Oct 2024 10:00:00 GMT

Les applications thérapeutiques des ultrasons sont nombreuses, notamment en neurologie. Prédire en temps réel le champ de pression acoustique à appliquer est indispensable. C’est ce que permet de faire l’algorithme SplineBeam développé par une équipe du SHFJ en collaboration avec le CEA-List, NeuroSpin et le CHU Grenoble-Alpes.

Micelles : comment améliorer l’efficacité radiothérapeutique lorsque les tumeurs résistent ?

Wed, 23 Oct 2024 10:00:00 GMT

Des équipes du SCBM et du SHFJ, en collaboration avec le CEA-Jacob et l’ISMO ont développé une micelle perfluorée biocompatible pour améliorer l’efficacité des radiothérapies et qui serait particulièrement intéressante dans des environnements tumoraux radiorésistants.

Study of subcortical neuromodulatory systems alteration in Alzheimer's disease and related disorders

Wed, 16 Oct 2024 10:00:00 GMT

A team from GHU Paris and SHFJ has used brain MRI to study the integrity of the locus coeruleus and nucleus basalis of Meynert in patients with early-onset Alzheimer's disease (AD), age-related TDP-43 encephalopathy (LATE) and fronto-temporal dementia (FTD). Both structures are altered in early AD, LATE and probably FTD, making these neuromodulatory areas potential therapeutic targets

PET image reconstruction by deep learning with uncertainty estimation in the ClearMind gamma photon detector

Mon, 07 Oct 2024 10:00:00 GMT

Three DES and DRF laboratories have developed an innovative Machine Learning algorithm to improve the reconstruction of PET images acquired as part of the ClearMind project, a technology based on the detection of gamma photons by a monolithic lead tungstate crystal detector. A step towards more accurate PET imaging

La microfluidique en gouttelettes et l'IA pour détecter la résistance à la colistine

Mon, 30 Sep 2024 10:00:00 GMT

Une collaboration dirigée par le LERI (SPI/DMTS) a mis au point un dispositif de microfluidique en gouttes pour tester rapidement et efficacement la susceptibilité à la colistine, un antibiotique pour lequel des phénomènes de résistance bactérienne ont été observés. L’Intelligence artificielle complète la méthode pour faciliter l’étape d’analyse des images et augmenter la sensibilité du test.

L’épigénétique comme biomarqueur d’efficacité thérapeutique contre le déficit en transporteur de la créatine lié à l’X.

Tue, 17 Sep 2024 10:00:00 GMT

Des résultats obtenus par une équipe du SPI, en collaboration avec CERES Brain Therapeutics et l’Université de Sharjah (Emirats arabes unis), indique que le niveau de méthylation de l’ADN pourrait constituer un biomarqueur intéressant de l’efficacité thérapeutique d’un traitement potentiel du déficit en transporteur de la créatine lié à l’X.

PET imaging evaluation of the central effects of a drug-candidate to aid smoking cessation

Thu, 29 Aug 2024 10:00:00 GMT

A BioMaps team has used PET imaging to monitor glucose metabolism as a marker of the cerebral impact of smoking cessation, as well as the effects of a promising drug-candidate for the treatment of such cessation. By revealing the restoration of normal activity in the brain area associated with craving, these results offer hope for smoking cessation in humans

Marquage par échange isotopique : après l’hydrogène et le carbone, le soufre ?

Tue, 09 Jul 2024 10:00:00 GMT

Une équipe du SCBM met au point une méthode d’échange isotopique du soufre pour le marquage de molécules biologiquement actives. Telle une plateforme isotopique multi-échangeable, le procédé permet également un échange isotopique du carbone et d’hydrogène donnant accès à un grand nombre d’isotopologues. L’équipe met en avant le potentiel de la méthode pour vérifier l’authenticité de molécules organiques commerciales.

Nanosciences: Towards a new type of micellar phototherapy?

Wed, 12 Jun 2024 10:00:00 GMT

SCBM researchers have designed nanometric micelles that can be activated by light and constructed by self-assembly of amphiphiles derived from ferrocene, which carries a hidden therapeutic activity in the absence of activation.

Breaking a bridge and rebuilding it to radiolabel a molecule

Fri, 24 May 2024 10:00:00 GMT

Researchers at BioMaps have developed a "re-bridging agent" for the radiolabelling of biomolecules containing disulphide bridges. Their strategy has enabled several molecules of therapeutic interest to be labelled with fluorine-18, copper-64 and zirconium-89.

Response to intra-tumoral immunotherapy assessed by immunoPET in mice

Fri, 19 Apr 2024 10:00:00 GMT

A team from BioMaps (SHFJ), in partnership with the Gustave Roussy Institute, has used immunoPET imaging to assess the influence of tissue distribution on the efficacy of cancer immunotherapy, administered intra-tumor and intravenously in mice. Intratumoral administration is more effective and reduces overall exposure of organs at risk

Nanometric micelles for targeted delivery of a prodrug against atherosclerosis

Thu, 14 Mar 2024 11:00:00 GMT

Teams from SCBM and SIMoS (DMTS) have developed nano-micelles for the vectorization of an active principle which regulates cholesterol metabolism towards atherosclerotic lesions.

Improved diagnosis of acute hepatic porphyrias using mass spectrometry

Fri, 23 Feb 2024 11:00:00 GMT

A collaborative study between SPI and a team from Hôpital Louis Mourier demonstrates the contribution of liquid chromatography coupled with mass spectrometry to the day-to-day analytical needs of a clinical laboratory. Application to the rapid quantification of biomarkers in acute hepatic porphyrias.

Functionalization of the B subunit of Shiga toxin as a vaccine tool

Fri, 26 Jan 2024 11:00:00 GMT

Researchers at SIMoS (DMTS) describe the synthesis, engineering and evaluation of the properties of the B subunit of bacterial Shiga toxin (STxB), administered mucosally, as a vaccine tool. Their results confirm the value of using a synthetic STxB in an anti-tumor and anti-infectious vaccination strategy.

Validation of a new elasticity biomarker for biological tissue diagnosis

Wed, 24 Jan 2024 11:00:00 GMT

SHFJ researchers have validated the use of a new biomarker, the nonlinear shear modulus, to measure the elasticity of biological tissues, by comparing results obtained using echography with those obtained using MRI imaging and digital simulation. This biomarker is of particular interest for the diagnosis of certain breast cancers.

Combining in silico and in vitro strategies for better therapeutic antibodies: an example with derivatives of adalimumab, an anti-TNF agent

Thu, 18 Jan 2024 11:00:00 GMT

SIMoS researchers have shown that by combining two approaches, in silico and in vitro, it is possible to select therapeutic antibodies whose functionality is preserved while reducing the risk of them inducing an undesirable immune response.

Cardiac transplantation: better graft eligibility criteria thanks to metabolomics?

Wed, 15 Nov 2023 11:00:00 GMT

In a study conducted by a team from the Marie Lannelongue Hospital, SPI researchers have established a difference between the metabolomic profiles of heart grafts harvested from pigs in a state of encephalic death or dead after controlled circulatory arrest. This work contributes to the exploration and validation of the use of hearts taken from people who have died after controlled circulatory arrest as a new source of grafts.

Chimie : passer par le radical anion du CO2 pour le radiomarquage de médicament est possible

Tue, 24 Oct 2023 10:00:00 GMT

Des chercheurs de l'institut montrent qu’une stratégie fondée sur la formation du radical anion CO2●- marqué au carbone 14 ou carbone 11 s’avère payante pour radiomarquer en conditions douces des médicaments.

Impact of metabolic variations on PET imaging of neuroinflammation in humans

Thu, 12 Oct 2023 10:00:00 GMT

Researchers at BioMaps evaluated the effect of several factors on the distribution of [18F]DPA-714 in 201 subjects who participated in SHFJ PET imaging protocols to better understand the role of neuroinflammation in various neurological diseases. They conclude that measures of individual metabolism are important in image interpretation.

PET imaging monitoring of an antibody targeting endothelin receptors expressed by glioblastoma tumors

Thu, 07 Sep 2023 10:00:00 GMT

Researchers at BioMaps (SHFJ) and SPI (DMTS) have studied the pharmacokinetics of a novel immuno-radioligand targeting the endothelin A receptor (ETA), overexpressed in many cancers, particularly glioblastoma. The immunoPET imaging approach used in this study in a preclinical model confirms the theranostic potential of this antibody.

Longitudinal monitoring of tauopathy in PET imaging to better understand the various modalities of clinical evolution of Alzheimer's disease

Wed, 02 Aug 2023 10:00:00 GMT

A joint team from GHU Paris and BioMaps (SHFJ) conducted a 2-year longitudinal study of 27 people with Alzheimer's disease, tracking the progression of tau pathology measured by PET imaging, of cortical atrophy using MRI, and their links with cognitive decline.

The "rabbit motif" in 18F-DOPA PET imaging for a simplified diagnostic evaluation of parkinsonian syndromes

Tue, 23 May 2023 10:00:00 GMT

BioMaps researchers compared the diagnostic performance of the rabbit visual pattern observed in 18F-DOPA PET imaging with the standard procedure approved by the international nuclear imaging societies for the diagnosis of parkinsonian syndromes in PET/MRI and obtained encouraging results, which may validate the clinical utility of such a model

Radiomarquage du crizotinib au fluor-18 : un nouvel outil pour suivre par TEP la biodistribution de ce médicament

Thu, 27 Apr 2023 10:00:00 GMT

Des chercheurs du SHFJ ont mis au point la radiosynthèse au fluor-18 du crizotinib, un médicament qui ne pénètre pas dans le cerveau. Ce nouvel outil pour l’imagerie TEP permettra d’explorer de futures stratégies visant à faire passer la barrière hémato-encéphalique à ce médicament pour traiter certaines métastases cérébrales.

Combining neuroanatomical markers to strengthen the diagnosis of fetal alcohol spectrum disorder

Mon, 13 Mar 2023 11:00:00 GMT

By analyzing brain imaging data, researchers from InDEV (NeuroSpin / UMR NeuroDiderot) have identified recurrent abnormalities in subjects with fetal alcohol syndrome, the combination of which could have a particularly interesting diagnostic value for non-syndromic forms of fetal alcohol spectrum disorders.

Platinum nanoparticles to improve radiotherapy ? PET imaging provides answers

Tue, 21 Feb 2023 11:00:00 GMT

Researchers from the SHFJ laboratory at ISMO have demonstrated the value of platinum nanoparticles as potential radiosensitizing agents for radiation therapy.

Development of a new radiolabeling strategy in immunoPET for precision imaging

Tue, 21 Feb 2023 11:00:00 GMT

Researchers from the BioMaps laboratory (SHFJ) and the Molecular Engineering for Health Service (SIMoS, DMTS) developed an enzymatic approach for radiofluorination of an anti-PD-L1 Fab and compared its in vivo properties to the same Fab stochastically labeled by two conventional methods.

Glioblastoma: Does focused ultrasound increase the therapeutic efficacy of cetuximab?

Wed, 15 Feb 2023 11:00:00 GMT

Researchers from the SHFJ, in collaboration with NeuroSpin, show that the use of focused ultrasound does not increase the therapeutic effects of cetuximab on glioblastoma although the opening of the blood-brain barrier is transiently effective.

From a marine toxin to a melanocortin receptor antagonist, a therapeutic target for energy metabolism disorders

Thu, 09 Feb 2023 11:00:00 GMT

A SIMoS team discovered a toxin in the venom of a marine cone that it engineers into a high affinity antagonistic peptide for the melanocortin receptor, a major regulator of energy homeostasis. A step towards the development of innovative treatments for certain eating disorders

Detection of monkeypox: Mass spectrometry proves once again its effectiveness

Mon, 28 Nov 2022 11:00:00 GMT

A Li2D team has released the peptidomic profile of the virus that causes monkeypox, which they established using tandem mass spectrometry. These data should help to better understand the evolution of the epidemic and allow the creation of targeted tests to potentially detect the threat more quickly and prevent a new epidemic.

Dual labeling and digital imaging for the evaluation of protein-drug conjugates in preclinical models

Mon, 22 Aug 2022 10:00:00 GMT

A team from SIMoS, in collaboration with the SCBM (DMTS), has developed an original bioanalytical approach based on the double 14C-3H isotopic labeling of an antibody-drug conjugate, allowing the simultaneous in vivo monitoring of the two components in mouse models as well as their precise quantification in the organs.

Fight against antibiotic resistance: two additional rapid lateral flow immuno-assays

Tue, 02 Aug 2022 10:00:00 GMT

Researchers at the LERI together with the AP-HP have developed 2 rapid and inexpensive immunological tests to detect antibiotic resistance. The novelty: the tests detect the activity of bacterial enzymes that hydrolyze extended-spectrum cephalosporins.

A novel fluorine-18 thiol carrier for labeling biomolecules used in PET imaging

Tue, 28 Jun 2022 10:00:00 GMT

Radiochemists from the BioMaps unit (SHFJ) have developed and automated the synthesis of an 18F-fluoropyridine containing a thiol function (-SH), allowing its conjugation to model biomolecules within 45 minutes. A step towards rapid radiolabeling of complex biological molecules for PET imaging.

New radioligands for anti-PD-1/PD-L1 immunoPET

Tue, 12 Apr 2022 10:00:00 GMT

Researchers from the SHFJ and the DMTS have developed optimized radioligands for immunoPET imaging. The objective is to better predict the effectiveness of anti-PD1/anti-PDL1 immunotherapy used to fight certain cancers.

Facilitating access to deuterated and tritiated molecules: towards more diversity!

Wed, 06 Apr 2022 10:00:00 GMT

Researchers from the SCBM describe a hydrogen isotope labeling process that is easy to implement and whose starting point is a "simple" mixture, in a solvent, of the product to be labeled with a pre-catalyst. Explanations of this process which finds applications in many fields including drug development or medical imaging.

Hybrid PET/MRI imaging, a unique examination to improve the detection of epileptogenic lesions

Tue, 05 Apr 2022 10:00:00 GMT

A team from BioMaps (SHFJ), in collaboration with several hospital groups, shows that hybrid PET/MRI imaging significantly improves the detection of epileptogenic foci and, consequently, the outcome of surgical treatment of epilepsy.

Alzheimer's: PET imaging of tau protein predicts cognitive decline and progression of brain atrophy

Sun, 03 Apr 2022 10:00:00 GMT

A joint team from GHU Paris and SHFJ shows the predictive value of PET imaging data of the Tau protein in the progression of Alzheimer's disease.

Buprenorphine/benzodiazepine interaction: why is it more dangerous?

Fri, 25 Mar 2022 11:00:00 GMT

A collaboration between the SHFJ and the UMR-S 1144 (University of Paris) shows that the deleterious effect of the buprenorphine/benzodiazepine combination would result from the combined action of each drug on its target.

Deeptope: accelerating the development of therapeutic antibodies via high-throughput functional tests

Mon, 29 Nov 2021 11:00:00 GMT

Deeptope, founded in February 2021 from a technology developed at the DMTS Laboratory of Cellular Immunology and Biotechnology (LICB), is a company of therapeutic antibody engineering that provides antibody optimization and characterization services to biotech or pharmaceutical firms with the goal of increasing the quality of antibodies in a very short timeframe.

Multiparametric PET-MRI imaging: toward a biological characterization of tumors at the supervoxel level

Wed, 10 Nov 2021 11:00:00 GMT

A collaborative study led by BioMaps researchers (SHFJ) demonstrates that fully integrated quantitative multiparametric analysis of non-small cell lung cancer in hybrid 18F-FDG PET/MRI 3T imaging is clinically feasible and could enable biological characterization of tumors at the supervoxel scale.

PET imaging of tau and amyloid deposits improves the diagnosis of progressive amnesia

Thu, 04 Nov 2021 11:00:00 GMT

Researchers from BioMaps (SHFJ) and the Service de Neurologie de la Mémoire et du Langage (Hôpital Ste-Anne) show, through amyloid and tau molecular imaging in patients followed for 2 years, that the diagnosis of progressive amnesia in the elderly is not necessarily Alzheimer's disease and may be caused by other mechanisms clearly distinguishable from it.

Characteristics of the initial symptoms of Alzheimer's disease in young patients

Thu, 10 Jun 2021 10:00:00 GMT

Researchers from BioMaps (SHFJ) and the Department of Memory and Language Neurology (Ste Anne's Hospital) studied the early clinical signs of Alzheimer's disease (AD) reported by young patients (< 62 years old) compared to those reported in classic AD of the elderly (> 65 years old). They show that these signs are misleading and often appear in the professional context.

Evaluation of the immunogenicity of peptide-drugs containing non-natural modifications

Tue, 01 Jun 2021 10:00:00 GMT

A team from SIMoS (DMTS) in collaboration with Sanofi shows that the introduction of non-natural sequences into an immunogenic peptide attenuates the immune response against this peptide, an approach that could guide the design of less immunogenic, and therefore more effective, therapeutic peptides.

PET imaging reveals the neuropharmacology of buprenorphine

Wed, 05 May 2021 10:00:00 GMT

Researchers at BioMaps (SHFJ) have succeeded in determining the interaction dynamics of buprenorphine, an opioid drug with a particularly complex pharmacology, with its brain receptors in vivo. To do so, they developed an original PET imaging approach based on the use of the radiolabeled molecule (11C-buprenorphine).

How works Mambalgin-1, an analgesic peptide from black mamba venom

Thu, 08 Apr 2021 10:00:00 GMT

Teams from IPMC and SIMoS (DMTS) defined the molecular determinants of the interaction between Mambalgin-1, an analgesic peptide isolated from black mamba venom, and its target, ASIC1 (Acid-Sensing Ion Channels), to model, using molecular dynamics, this complex. The resulting model provides clues to develop blockers of ASIC1, interesting targets for clinical pain relief applications.

Salmonellosis and shigellosis: a monoclonal antibody induces cross-protection

Thu, 25 Mar 2021 11:00:00 GMT

Researchers at CEA-Joliot (SPI unit in collaboration with SIMoS unit) have developed a monoclonal antibody directed against a common region of two proteins of the bacteria Shigella and Salmonella and capable of inducing cross-protection against infections caused by these bacteria.

Première étape vers un test quantitatif par spectrométrie de masse pour le diagnostic spécifique de la COVID-19 ?

Tue, 09 Mar 2021 11:00:00 GMT

Le LEMM, en collaboration avec le LI2D et l’AP-HP, développe un test de diagnostic spécifique de la Covid-19 par spectrométrie de masse qui permettrait aussi la quantification de la charge virale du patient. Objectif à terme : adapter la méthode pour la rendre plus sensible et compatible avec les équipements d’analyse des hôpitaux.

A micellar probe for fluorine magnetic resonance tumor imaging

Thu, 04 Mar 2021 11:00:00 GMT

A SCBM (DMTS) team, in collaboration with researchers at NeuroSpin and I2BC, is describing micellar nanometric vectors targeting tumors that have been imaged by fluorine magnetic resonance imaging (MRI). The observed 19F signal made it possible to precisely delimit the volume of the tumor zone in a mouse model and to quantify the probe accumulated in the target tissue.

Carbon labeling with light

Wed, 24 Feb 2021 11:00:00 GMT

Researchers from the LMC (DMTS), in collaboration with a team from AstraZeneca, have developed a labeling method, based on the exchange of carbon dioxide, simply using visible blue light and a photocatalyst.

Decompensated cirrhosis: involvement of amino acid metabolism in systemic inflammation

Mon, 14 Dec 2020 11:00:00 GMT

A European study involving CEA-Joliot provides the first overview of the amino acids circulating in the blood of patients with decompensated cirrhosis and concludes that there is a strong redistribution of their metabolism in order to provide the fuel necessary for the intense inflammatory response.

World Antimicrobial Awareness Week: the Institute continues its actions

Thu, 19 Nov 2020 11:00:00 GMT

The recent publication, in the journal Diagnostics, of a collaborative study associating AP-HP, NG-Biotech and a team from the Institute, is an opportunity to recall the Institute's commitment to the development of means of detecting antimicrobial resistance, a global phenomenon in the WHO's sights, as recalled by the World Antimicrobial Awareness Week.

Mambaquaretin: therapeutic and diagnostic interest?

Tue, 10 Nov 2020 11:00:00 GMT

In pursuing their work on mambaquaretin, SIMoS researchers conducted a collaborative study confirming the therapeutic potential of the toxin and paving the way for its use as a diagnostic tool.

Permeabilizing the blood-brain barrier to deliver therapeutic antibodies into the brain? ImmunoPET imaging provides answers

Tue, 06 Oct 2020 10:00:00 GMT

Researchers from SHFJ, NeuroSpin and DMTS have demonstrated, by immunoPET imaging, the impact of transient BBB permeabilization on brain exposure to an anti-EGFR antibody. Promising prospects for targeted immunotherapy of glioblastoma.

Development of a general strategy for the isotopic labelling of carbamates by incorporation of CO2

Thu, 10 Sep 2020 10:00:00 GMT

In a study published in Chemical Communications, the Joliot Institute Carbon labeling laboratory (LMC), in collaboration with the SHFJ, provides proof of concept of a "click" strategy for carbon isotope marking of pharmaceutical molecules containing carbamates.

SARS-CoV-2 detection: mass spectrometry shows its potential for rapidity.

Thu, 06 Aug 2020 10:00:00 GMT

A team from SPI in Marcoule detected by mass spectrometry, in 3 minutes and without specific reagents, signature peptides of the SARS-CoV-2 virus in clinical samples (nasopharyngeal swabs). It thus provides a proof of concept of the use of this method as a possible alternative to PCR, currently the reference method.

Mapping of normal brain aging: unprecedented results from the SENIOR cohort

Tue, 04 Aug 2020 10:00:00 GMT

The SENIOR study, conducted by several NeuroSpin teams, consists in monitoring, since March 2012, a cohort of 100 subjects aged 50 to 70 years by annual MRI imaging over a period of 10 years, to establish a normal aging brain imaging biomarkers mapping. This publication in Alzheimer's Research & Therapy describes the baseline experimental protocol and presents first promising results.

Mapping of Ebola T-cell response: towards a new vaccine ?

Wed, 24 Jun 2020 10:00:00 GMT

SIMoS researchers, in collaboration with Genopole, Excellgene, Vaxeal holding SA (Switzerland), used a large-scale approach to map and characterize the response of CD4 T-cells from healthy donors, against two proteins from the Ebola-Zaire virus. They observed a strong response to the viral nucleoprotein (NP) and suggest that components of NP may be included in the design of new Ebola vaccines.

Salmonellosis and shigellosis: first demonstration of cross-protection induced by virulence factors SipD and IpaD

Mon, 22 Jun 2020 10:00:00 GMT

SPI researchers show for the first time, in a mouse model, the induction of cross-protection against Salmonella and Shigella infections, two pathogenic bacteria responsible for gastrointestinal diseases (typhoid, dysentery among others), one of the main causes of morbidity and mortality in several regions of Africa and Asia.

How the identification of attenuated forms of the SARS-CoV-2 virus could help to control the current epidemic ?

Tue, 12 May 2020 10:00:00 GMT

An opinion article, published in Environmental Microbiology, and written by an international consortium initiated by three researchers of Joliot Institute, proposes an original way of research on Covid-19 through the identification by sequencing of attenuated variants of the SARS-CoV-2 virus in populations at risk with little or no symptoms.

Innovative approach to radiolabel peptides with fluorine-18 for PET imaging

Mon, 17 Feb 2020 11:00:00 GMT

Radiochemists from the BioMaps unit (SHFJ) have developed and automated a new fluor-18 radiolabelling method for peptides used to characterize specific pathological molecular signatures and thus target treatments. Peptides were conjugated to a specific tag, then radiolabeled in a single step under mild conditions, making this approach an innovative solution for PET imaging of peptides labeled with fluorine-18.

Lassa fever: a vaccine soon to be tested.

Wed, 09 Oct 2019 10:00:00 GMT

Researchers from Pasteur Institute, in collaboration with seven research teams, including SPI (LI2D/Marcoule), developed and evaluated the efficacy of several vaccine candidates against the virus responsible for Lassa haemorrhagic fever, endemic in Western Africa. They identified one of them as being the most effective, likely to quickly enter clinical trials in humans. Results are published in the journal Science Translational Medicine.

See a tumor in PET imaging by « click-chemistry » in vivo

Tue, 03 Sep 2019 10:00:00 GMT

A new PET imaging method by antibody pretargeting was developed at SHFJ, in collaboration with teams of SCBM and SPI. It consists in reacting in vivo a molecule labeled with 18Fluor with an antibody previously fixed on a tumor and this, in an extremely fast and selective manner, thanks to a « click-chemistry » reaction. The very good results obtained allow to consider the use of pre-targeted antibodies in nuclear medicine.

A new biomarker to predict tumor progression from whole body PET images.

Tue, 16 Jul 2019 10:00:00 GMT

The SHFJ/IMIV laboratory (Inserm 1023/CNRS/CEA/UP-Sud), in collaboration with hospital-university teams, has shown that, in patients with advanced-stage large cell lymphoma (B type), automatic quantitative measurements of tumor dissemination detected by whole-body PET imaging have a predictive value of progression-free survival (tumor stabilization) and overall survival.

A new generation of nanovectors for anticancer therapies.

Wed, 12 Jun 2019 10:00:00 GMT

As part of a collaboration with MIRCen (Jacob Institute), researchers of SCBM have developed functional micellar vectors that can effectively target tumors and whose therapeutic activity is intrinsically carried by the constitutive unit of the micelle. This combination leads to better drug load and avoids premature drug release.

A promising therapeutic innovation for creatine transporter deficiency.

Fri, 17 May 2019 10:00:00 GMT

Two teams from JOLIOT (SPI / SCBM), in collaboration with the University of Cincinnati, confirm the interest of a drug candidate to treat the congenital creatine deficiency syndrome, a rare neurological childhood disease, responsible for developmental delays and intellectual disability. The results obtained in an animal model of the disease show that it is possible to administer, nasally, dodecyl creatine ester-loaded microspheres, thus improving the cognitive functions of treated animals.

« Click and Release » chemistry for the targeted delivery of drugs in vivo

Fri, 15 Mar 2019 11:00:00 GMT

A team from the SCBM, in collaboration with the SPI, the IC2MP and the University Hospital of Poitiers, has developed a bioorthogonal chemistry strategy that allows, in vivo, the controlled release of active ingredients contained in micelles-targeting cancerous tumors. These results pave the way for new strategies for targeted drug delivery.

Pain: a promising toxin isolated from a spider venom

Mon, 11 Mar 2019 11:00:00 GMT

A collaboration between SIMOPRO, Sanofi R & D, Smartox Laboratories and the Thorax Institute, has isolated a toxin with antinociceptive properties from a high-throughput electrophysiological screening of a collection of more than 100 venoms. Cyriotoxin-1a has been identified, sequenced, chemically synthesized and functionally characterized - from cell to organism in vivo.

Towards a better detection of glioblastoma infiltration

Tue, 26 Feb 2019 11:00:00 GMT

Glioblastoma is a very aggressive cancer of the central nervous system, mainly because of its ability to infiltrate the surrounding areas. A collaboration led by a team of SHFJ and involving NeuroSpin demonstrates the interest of two imaging techniques for the early detection of tumor infiltration.

European funding for better management of liver diseases

Fri, 01 Feb 2019 11:00:00 GMT

Europe is committed to better diagnostic and therapeutic management of patients with severe forms of cirrhosis. It finances the MICROB-PREDICT consortium, which aims to better understand the role of the human microbiome in the pathogenesis and evolution of cirrhosis. Final goal is to uture personalized therapeutic strategies and diagnostic tools. The SPI (Joliot Institute) is the main project lead for the CEA.

Evolution of Alzheimer's disease : a dual role of the neuroimmune reaction

Thu, 10 Jan 2019 11:00:00 GMT

A collaboration involving the Sainte-Anne Hospital, the SHFJ, the Saint-Antoine research center and the ICM identified, through a PET brain imaging study in patients with Alzheimer's disease, two distinct kinetic profiles of the cerebral neuroimmune response, that impact the disease progression differently. Researchers propose an original model of neuroinflammation, likely to open new therapeutic avenues.

Physicists and pharmacologists join forces to better understand the biology of the blood-brain barrier.

Thu, 20 Dec 2018 11:00:00 GMT

Thanks to complementary imaging techniques, researchers from the SHFJ and NeuroSpin have shown that the physical blood-brain barrier (BBB) disruption is not necessarly enough to deliver some drugs into the brain, especially when there are recognized and supported by efflux transporters.

Cerebral lymphoma: a new indication for [18F]Fludarabine?

Mon, 08 Oct 2018 10:00:00 GMT

A SHFJ research team (LDM-TEP, GIP Cyceron, Caen) has previously developed and produced a radiopharmaceutical, the [18F]-Fludarabine, to detect lymphomas using PET scan. The team has recently conducted a preclinical study that shows the molecule can help in diagnosis of cerebral lymphoma by differentiate it from glioblastoma, the main brain tumor. A clinical study should be launched before the end of the year.

A reliable and accessible algorithm based on EEG to diagnose states of consciousness

Fri, 05 Oct 2018 10:00:00 GMT

An international collaboration, led by the Institut du Cerveau et de la Moelle épinière – ICM (Brain & Spine Institute) and involving researchers from NeuroSpin, offers a new electroencephalogram (EEG) tool that helps the diagnosis of disorders of consciousness. Unlike other tools developed so far and dedicated to a few expert centers, “DoC-Forest” would be accessible to most of the hospitals worldwide.

Mass spectrometry for quality control of vaccines

Thu, 05 Jul 2018 10:00:00 GMT

A SPI Research Team (LI2D, Marcoule), in collaboration with CIRAD and AU-PANVAC, proposes a new quality control technique for veterinary vaccines, based on very high resolution mass spectrometry. This strategy, based on the use of an ad hoc database to measure the proportion of antigens and contaminants in the vaccine preparation, will improve the quality control of vaccines against contagious caprine pleuropneumonia.

LIFEx increasingly popular for characterizing tumor heterogeneity in medical imaging

Thu, 05 Jul 2018 10:00:00 GMT

IMIV unit (SHFJ), in collaboration with the Gustave Roussy Institute, has developed the free software platform LIFEx that allows to characterize the tumor heterogeneity from any type of medical images: PET, MRI, scanner, ultrasound. With nearly 900 members, this platform has an international success because it facilitates the realization of radiomic studies, conducted in the context of personalized medicine.

A SIMOPRO project supported by SATT Paris-Saclay

Wed, 30 May 2018 10:00:00 GMT

A SIMOPRO project supported by SATT Paris-Saclay: in vivo validation of the efficacy of the DTR8 molecule, developed and patented at SIMOPRO (Department of Medicines and Technologies for Health) in collaboration with Inserm, as a treatment for glomerulonephritis rapidly progressive.

Toxins, vaccines, biobetters: a mission at the Butantan Institute of São Paulo

Fri, 25 May 2018 10:00:00 GMT

Last April, a delegation of experts from the DRF visited colleagues at the Butantan Institute of São Paulo, a biomedical research center that has had close links with several researchers at the Joliot Institute since 2014. This mission is is concluded by the signing of a framework agreement between the two institutes in the field of therapeutic and vaccine innovation.

18F-Fludarabine for Lymphoma Imaging: A First Clinical Study

Wed, 23 May 2018 10:00:00 GMT

The SHFJ LDM-PET team (GIP Cyceron, Caen), in collaboration with the University Hospital of Caen, successfully used, for the first time in the clinic, the radiopharmaceutical drug developed and produced by the researchers of the team. , the [18F] Fludarabine. This drug, which is innovative for lymphoproliferative diseases, has been shown to be more effective in terms of specificity and sensitivity than its current counterpart, [18F] FDG.

A pharmacokinetic model for more accurate PET imaging of neuroinflammation

Thu, 22 Feb 2018 11:00:00 GMT

Research Teams from SHFJ, MIRCen and NeuroSpin tested a pharmacokinetic analysis model of Positron-emission tomography (PET) data at 18F-DPA-714, taking into account endothelial cell activity not specifically associated with an inflammatory state. This model allows a more precise interpretation of PET images of neuroinflammation present in most neurodegenerative pathologies.

Ultrasound to improve drug delivery to the brain

Mon, 19 Feb 2018 11:00:00 GMT

Researchers from NeuroSpin (Frédéric Joliot Institute/CEA) and MIRCen (François Jacob Institute/CEA Institute of Biology) have just developed an ultrasound device guided by magnetic resonance imaging (MRI) to increase temporarily and locally the vascular permeability in non-human primates, which could be used to effectively deliver drugs to the brain.

Transcription regulation by the Mediator: recent progress

Wed, 17 Jan 2018 11:00:00 GMT

Julie Soutourina (I2BC@Saclay / SBIGeM) was invited by Nature Reviews Molecular Cell Biology to publish a review on the molecular functioning of the Mediator, a multi-protein complex, conserved from yeast to humans, and essential to the regulation of the expression of genes. Potential therapeutic approaches targeting the Mediator (cancer, fungal infections) are also adressed.

Antibiotic resistance: a Joliot Institute project funded by EIT Health

Wed, 29 Nov 2017 11:00:00 GMT

A SPI/LERI Research Team has recently developed new test strips for the detection of some multi-resistant bacteria. A hospitalization project for these high-speed screening tests will be rolled out in 2018 with funding from EIT Health.